



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life- improving drugs. For more than 30 years, we’ve been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in ove countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug develop process.

We help change people’s lives for the better every single day. It’s what we are passionate about.

## STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$73.86
Change (%)	▼ 2.95 (3.84%)
Volume	154,215
52 Week Low	\$43.12
Market Cap	\$4,798,452,352
Rolling EPS	1.69
PE Ratio	45.4763
Shares Outstanding	62,471,714
Data as of 07/27/17 4:00 p.m. ET	



## NEWS & EVENTS

Date	Title
------	-------

Date	Title
------	-------

07/25/17	PRA Health Sciences to Report 2nd Quarter 2017 Earnings
06/19/17	PRA Health Sciences and Jumo Announce Partnership
05/22/17	PRA Health Sciences Named International Clinical Research Company of the Year

08/08/17	Q2 2017 PRA Health Sciences Inc Earnings Conference Call
9:00 a.m. ET	

## SEC FILINGS

Filing Date	Form
07/14/17	4
07/14/17	4
07/14/17	4
06/02/17	8-K

## BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Linda S. Grais, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Ali J. Satvat	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)